Competition is not a problem at all, only Rebiff could create competition problems to Avonex, not any other company could be affected by competition, not xoma.
UbsW put a strong buy on Dna, they claimed that xanelim will have a lot of competition, a smaller $1B market to share,$100Ms in 04, and immunesuppression perception problems, all that better than Amevive, the also put a buy on Icos and their IC747 (jumbo!)with their Lfa1 xanelim proof of concept also on the way, and medi507, is their view, not mine, send e-mail to kim guy, kim gal and the other guy who publihsed the report. |
